• E. coli engineered to synthesize rhododendron-derived compounds with anticancer, anti-HIV, antidiabetic, anti-inflammatory properties. • Kobe University’s rational design strategy enables scalable, industrial production of diverse drug candidates. • Bioengineered bacteria produce complex natural products traditionally extracted from plants, reducing reliance on wild sources. • Platform allows rapid optimization of metabolic pathways for higher yields and cost‑effective manufacturing. • Potential to accelerate drug discovery pipelines by providing ready access to multi‑functional therapeutic molecules. • This breakthrough demonstrates the power of synthetic biology in transforming natural product drug development.
Article Summaries:
- Bioengineered E. coli bacteria can now produce a group of compounds with anticancer, anti-HIV, antidiabetic and anti-inflammatory activities. The Kobe University achievement is the result of a rational design strategy that yields a platform for the industrial production of drug candidates.
Sources: